Logo image
Optimizing antenatal corticosteroid therapy
Journal article   Open access   Peer reviewed

Optimizing antenatal corticosteroid therapy

M.W. Kemp, A.F. Schmidt and A.H. Jobe
Seminars in Fetal and Neonatal Medicine, Vol.24(3), pp.176-181
2019
pdf
antenatal.pdfDownloadView
Author’s Version Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24-34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

Source: InCites

Metrics

221 File views/ downloads
102 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.72 Obstetrics & Gynecology
1.72.924 Preterm Birth Causes
Web Of Science research areas
Pediatrics
ESI research areas
Clinical Medicine
Logo image